Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
Clinical trial NCT02304159 · COMPLETED
Trial details
- NCT number
- NCT02304159
- Sponsor
- Tarek I. Hassanein, M.D., FACP, FAG, AGAF
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-01
- Primary completion
- 2017-08-01
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.